Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2025-06-26 00:00:00 ET · period of report 2025-06-25 · accession 0000950170-25-090198 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-26 | 2025-06-25 | CADL | Tak Paul Peter | CEO, Dir | A - Grant | $4.67 | +42.8K | 268.6K | +19% | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-25 | A | A | 42,826 | $4.67 | 268,566 | D | — | — |